Arabic Arabic English English French French German German
dark

Takeda Augments IO Portfolio with Third Build-to-Buy Acquisition in a Year

The planned acquisition will give Takeda full access to Adaptate’s antibody-based γδ T cell engager platform, which includes both pre-clinical and discovery assets. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Sanofi, Exscientia Expand in AI with Up-to-$5.2B Cancer, Immunology Alliance

Next Post

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Related Posts
Total
0
Share